GlassScriptPhysician profile
Mark T Peters
NPI 1386686137
$13,875.29
in general payments reported to CMS, 2019-2025
42 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,472 · 2020: $1,799 · 2021: $2,283 · 2022: $2,007 · 2023: $1,871 · 2024: $1,401 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,260 · Education: $54.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,260.22 |
| Education | $54.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,597.75 | 2019-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $2,022.96 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,827.18 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,154.49 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Insmed, INC. | $1,026.82 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $638.65 | 2019-2025 | |
| Grifols USA, LLC | $619.99 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $574.45 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $464.87 | 2023-2025 | Winrevair, Keytruda, Recarbrio |
| United Therapeutics Corporation | $390.18 | 2019-2025 | Tyvaso, Tyvaso |
| Pfizer INC. | $325.88 | 2019-2025 | |
| Mylan Specialty L.P. | $313.00 | 2019-2024 | Yupelri |
| Amgen INC. | $265.58 | 2023-2025 | Tezspire, Tavneos |
| Electromed, INC. | $207.08 | 2019-2024 | Smartvest |
| Penumbra, INC. | $169.12 | 2023 | Indigo System |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.